Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific spices up board

This article was originally published in The Gray Sheet

Executive Summary

John Pepper re-elected to Boston Scientific board after one-year hiatus as chairman of Procter & Gamble. Pepper, who served previously from 1999-2001, is currently a director for Xerox and Motorola as well as a Fellow of the Yale Corporation. He replaces Lawrence Horsch, who retired after serving on Boston Scientific's board since the company's acquisition of Scimed Life Systems in 1995, where he had been a director since 1977...

You may also be interested in...



Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.

Medicare-For-Hmmm: A Year Of House Hearings Show Democratic Disunity

Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.

UsernamePublicRestriction

Register

MT018347

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel